Drug Guide
Podofilox
Classification
Therapeutic: Genital warts treatment
Pharmacological: Antimitotic agent
FDA Approved Indications
- Treatment of external genital and perianal warts (condylomata acuminata) caused by human papillomavirus (HPV)
Mechanism of Action
Podofilox inhibits mitosis by depolymerizing tubulin, leading to inhibition of cell division and destruction of wart tissue.
Dosage and Administration
Adult: Apply a thin layer to the wart(s) twice daily for 3 days, then discontinue for 4 days; repeat if necessary.
Pediatric: Not recommended for use in children.
Geriatric: No specific dosage adjustment required; use with caution and monitor for local skin reactions.
Renal Impairment: No specific dose adjustment.
Hepatic Impairment: No specific dose adjustment.
Pharmacokinetics
Absorption: Minimal systemic absorption when applied topically.
Distribution: Localized action, systemic distribution negligible.
Metabolism: Metabolized locally in skin tissues.
Excretion: Excreted in skin tissues; negligible systemic excretion.
Half Life: Not applicable due to minimal systemic absorption.
Contraindications
- Hypersensitivity to podofilox or any component of the formulation.
Precautions
- Avoid application to large areas or mucous membranes to prevent systemic absorption.
- Use caution in pregnant or breastfeeding women; safety not established.
Adverse Reactions - Common
- Local skin reactions (pain, burning, erythema, erosion) (Common)
Adverse Reactions - Serious
- Serious skin ulceration or necrosis in case of overuse or accidental ingestion. (Rare)
Drug-Drug Interactions
- None well-defined; caution advised with other topical agents.
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Inspect the area of application for skin integrity and signs of adverse reactions.
Diagnoses:
- Risk for skin integrity disturbance.
- Knowledge deficit about treatment.
Implementation: Instruct patient on proper application technique, hand hygiene, and avoiding contact with uninvolved skin.
Evaluation: Monitor for resolution of warts and adverse skin reactions.
Patient/Family Teaching
- Apply medication as directed, avoid applying to other skin or mucous membranes.
- Wash hands thoroughly before and after application.
- Report excessive skin irritation, pain, or signs of infection.
Special Considerations
Black Box Warnings:
- None
Genetic Factors: None specified; no pharmacogenetic data required.
Lab Test Interference: None.
Overdose Management
Signs/Symptoms: Local skin irritation, ulceration, systemic toxicity if accidentally ingested or overapplied.
Treatment: Discontinue use immediately, wash affected areas, symptomatic treatment for skin reactions, seek medical attention if ingestion occurs.
Storage and Handling
Storage: Store at room temperature, 20°C to 25°C (68°F to 77°F).
Stability: Stable until expiration date printed on package.